Sugi Predict

Sugi Predict / Compounds / SCHEMBL25946385

SCHEMBL25946385

SCHEMBL25946385

CC1(NC(=O)OC2CCCC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 2/20 0.50
▸ CDK2 P24941 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ IDO1 P14902 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ MAPT P10636 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NAAA Q02083 2/20 0.36
▸ RET P07949 1/20 0.35
▸ CCNE1 P24864 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30817611 0.98 EPHX1 (0.49) EPHX1CDK2SMN1; SMN2CYP2C19IDO1
SCHEMBL31512311 0.94 EPHX1 (0.49) EPHX1CDK2SMN1; SMN2CYP2C19IDO1
SCHEMBL31512251 0.88 EPHX1 (0.44) EPHX1CDK2SMN1; SMN2CYP2C19IDO1
SCHEMBL20070374 0.87 EPHX1 (0.42) EPHX1CDK2SMN1; SMN2CYP2C19IDO1
SCHEMBL22856996 0.85 EPHX1 (0.41) EPHX1CDK2SMN1; SMN2CYP2C19IDO1
SCHEMBL20147528 0.83 EPHX1 (0.40) EPHX1CDK2SMN1; SMN2CYP2C19IDO1
SCHEMBL30685321 0.82 CCNE1 (0.43) EPHX1CDK2IDO1NPC1POLB
SCHEMBL20069526 0.80 EPHX1 (0.36) EPHX1CDK2SMN1; SMN2CYP2C19IDO1
SCHEMBL8928025 0.74 EPHX1 (0.50) EPHX1SMN1; SMN2CYP2C19IDO1ALDH1A1
SCHEMBL29749484 0.73 EPHX1 (0.48) EPHX1SMN1; SMN2IDO1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568948-A1 COMPOUNDS FOR TREATING CANCER Genesis Therapeutics, Inc. (US) 2025-06-18 — — EP disclosed
US-20250074895-A1 CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME BLUEPRINT MEDICINES CORPORATION 2025-03-06 — — US disclosed
WO-2024059010-A1 COMPOUNDS FOR TREATING CANCER GENESIS THERAPEUTICS, INC. (US) 2024-03-21 — — WO disclosed
US-11718603-B2 CDK2 inhibitors PFIZER INC. (US) 2023-08-08 — — US disclosed
WO-2023141852-A1 CDK2 INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF 益方生物科技(上海)股份有限公司 2023-08-03 — — WO disclosed
WO-2022135442-A1 CDK2 INHIBITOR AND PREPARATION METHOD THEREFOR 上海拓界生物医药科技有限公司 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074895-A1 CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME CDK2, CDK20, CDK2AP1 EPHX1 3845/4885CDK2 1/4885SMN1; SMN2 2137/4885
US-11718603-B2 CDK2 inhibitors CDK2, CDK1, CCNI EPHX1 2859/4885CDK2 1/4885SMN1; SMN2 1988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.